Picture of PAION AG logo

PA8 PAION AG Share Price

0.000.00%
de flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapValue Trap

Momentum

Relative Strength (%)
1m-2.47%
3m-1.47%
6m+766.84%
1yr+499.01%
Volume Change (%)
10d/3m-63.13%
Price vs... (%)
52w High-33.07%
50d MA-5.69%
200d MA+110.97%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital9.85%
Return on Equity-6.26%
Operating Margin8.73%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of PAION AG EPS forecast chart

Profile Summary

Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2022
Incorporated
June 30th, 2004
Public Since
March 29th, 2012
No. of Employees
68
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
de flag iconXETRA
Shares in Issue
7,133,699
Blurred out image of a map
Address
Heussstrasse 25, AACHEN, 52078
Web
https://www.paion.com/
Phone
+49 24144530
Contact
Ralf Penner
Auditors
Baker Tilly Gmbh & Co. KG

PA8 Share Price Performance

Upcoming Events for PA8

Paion AG Annual Shareholders Meeting

Q2 2023 Paion AG Earnings Release

Q3 2023 Paion AG Earnings Release

Similar to PA8

FAQ